Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
4
×
boston blog main
clinical trials
inclisiran
life sciences
national blog main
new york
new york blog main
new york top stories
4
×
regeneron pharmaceuticals
alnylam pharmaceuticals
boston top stories
national top stories
pcsk9 inhibitors
alirocumab
biotech
cholesterol
evolocumab
pcsk9
praluent
repatha
rna interference
sanofi
the medicines co.
data
deals
drugs
evercore isi
fda
heart attack
joseph swartz
ldl
mark timney
medicines co.
mt sinai hospital
novartis
peter wijngaard
prashant vaishnava
san francisco blog main
san francisco top stories
What
cholesterol
drug
4
×
medco
4
×
medicines
lowering
fda
new
twice
aces
acquire
agreed
alnylam
announced
based
big
billion
bringing
brings
cash
ceo
clears
closer
company
compound
data
deal
evidence
filing
flexible
heart
inched
inclisiran
key
lasting
long
looms
market
meant
medicine
morning
Language
unset
Current search:
drug
×
amgen
×
medco
×
" new york top stories "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms